Concepedia
Statistics
Publications
20
Citations
1.3K
H-Index
17
Active since
1994
Affiliations
Ionis Pharmaceuticals (United States)(Current)
University of California, Los Angeles
The Barbara Ann Karmanos Cancer Institute
UCSF Helen Diller Family Comprehensive Cancer Center
Texas Oncology
Andrew Dorr is an author at Ionis Pharmaceuticals (United States) specializing in medicine, oncology, and pharmacology.
Publications per year
1994–2025
Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer
John Nemunaitis, Jon Holmlund, Maura A. Kraynak et al. · Journal of Clinical Oncology · 1999 · 173 citations
Medicine, Oncology, Pharmacology +16
Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.
A R Yuen, Joanne Halsey, George A. Fisher et al. · PubMed · 1999 · 148 citations
Medicine, Oncology, Pharmacology +11
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
Casey Cunningham, Jon Holmlund, Joan H. Schiller et al. · PubMed · 2000 · 127 citations
Medicine, Oncology, Pharmacology +14
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
Anthony W. Tolcher, Leonard Reyno, Peter Venner et al. · PubMed · 2002 · 120 citations
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Rami S. Komrokji, John F. Seymour, Andrew W. Roberts et al. · Blood · 2015 · 119 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +10
1–5 of 20